1. Mineral Changes in Osteoporosis
- Author
-
Adele L. Boskey, Dan Faibish, and Susan M. Ott
- Subjects
medicine.medical_specialty ,Bone density ,Biopsy ,Osteoporosis ,Dentistry ,Placebo ,Bone and Bones ,Article ,Crystallinity ,Bone Density ,medicine ,Animals ,Humans ,Orthopedics and Sports Medicine ,Raloxifene ,Bone mineral ,Minerals ,medicine.diagnostic_test ,business.industry ,Spectrum Analysis ,General Medicine ,medicine.disease ,Surgery ,Bone mineral content ,business ,medicine.drug - Abstract
Bone mineral composition, crystallinity, and bone mineral content of osteoporotic patients are different from those of normal subjects. We review the evidence that these mineralization parameters contribute to the strength (fracture resistance) of bone and the methods that have been used to examine them. A specific example is provided from analysis of biopsies from the Multiple Outcomes in Raloxifene Evaluation trial. For the analyses, randomly selected biopsies from placebo, low-dose, and high-dose groups (n = 5 per group) obtained at time zero and 2 years after treatment were examined by infrared imaging spectroscopy. In all cases, comparable increases in mineral content were found, but there were no significant variations in mineral crystallinity.
- Published
- 2006
- Full Text
- View/download PDF